IL-1β reduces tonic contraction of mesenteric lymphatic muscle cells, with the involvement of cycloxygenase-2 and prostaglandin E2

British Journal of Pharmacology

Volumn 172, Issue 16, 2015, Pages 4038-4051

  Al Kofahi, M ^a   Becker, F ^a,b   Gavins, F N E ^a   Woolard, M D ^a   Tsunoda, I ^a   Wang, Y ^c   Ostanin, D ^c   Zawieja, D C ^d   Muthuchamy, M ^d   Von Der Weid, P Y ^e   Alexander, J S ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c Louisiana State University Health Sciences Center at Shreveport   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DICLOFENAC; GW 627368X; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR AFFECTING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PTGS2 PROTEIN, RAT; TUMOR NECROSIS FACTOR;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DISEASE; COLITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; IN VITRO STUDY; MALE; MOUSE; MUSCLE FIBER CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; KNOCKOUT MOUSE; LYMPH NODE; MESENTERY; METABOLISM; MUSCLE CELL; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; COLITIS; CYCLOOXYGENASE 2; DINOPROSTONE; INTERLEUKIN-1BETA; LYMPH NODES; MALE; MESENTERY; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE CELLS; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937517265     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13194     Document Type: Article

References (69)

1. Achen MG, Stacker SA, (2012). Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance. Growth Factors 30: 283-296.
2. Akiho H, Deng Y, Blennerhassett P, Kanbayashi H, Collins SM, (2005a). Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction. Gastroenterology 129: 131-141.
3. Akiho H, Lovato P, Deng Y, Ceponis PJ, Blennerhassett P, Collins SM, (2005b). Interleukin-4- and -13-induced hypercontractility of human intestinal muscle cells-implication for motility changes in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 288: G609-G615.
4. Aldrich MB, Sevick-Muraca EM, (2013). Cytokines are systemic effectors of lymphatic function in acute inflammation. Cytokine 64: 362-369.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676-1705.
7. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
8. Alitalo K, (2011). The lymphatic vasculature in disease. Nat Med 17: 1371-1380.
9. Baumgart DC, Sandborn WJ, (2012). Crohn's disease. Lancet 380: 1590-1605.
10. Beasley D, (1999). COX-2 and cytosolic PLA2 mediate IL-1beta-induced cAMP production in human vascular smooth muscle cells. Am J Physiol 276: H1369-H1378.
11. Becker F, Yi P, Al-Kofahi M, Ganta VC, Morris J, Alexander JS, (2014). Lymphatic dysregulation in intestinal inflammation: new insights into inflammatory bowel disease pathomechanisms. Lymphology 47: 3-27.
12. Becker F, Potepalov S, Shehzahdi R, Bernas M, Witte M, Abreo F, et al. (2015). Downregulation of FoxC2 increased susceptibility to experimental colitis: influence of lymphatic drainage function? Inflamm Bowel Dis 21: 1282-1296.
13. Belvisi MG, Saunders MA, Haddad E, Hirst SJ, Yacoub MH, Barnes PJ, et al. (1997). Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type. Br J Pharmacol 120: 910-916.
14. Benoit C, Gu Y, Zhang Y, Alexander JS, Wang Y, (2008). Contractility of placental vascular smooth muscle cells in response to stimuli produced by the placenta: roles of ACE vs. non-ACE and AT1 vs. AT2 in placental vessel cells. Placenta 29: 503-509.
15. Bridenbaugh EA, Wang W, Srimushnam M, Cromer WE, Zawieja SD, Schmidt SE, et al. (2013). An immunological fingerprint differentiates muscular lymphatics from arteries and veins. Lymphat Res Biol 11: 155-171.
16. Cao W, Fiocchi C, Pricolo VE, (2005). Production of IL-1beta, hydrogen peroxide, and nitric oxide by colonic mucosa decreases sigmoid smooth muscle contractility in ulcerative colitis. Am J Physiol Cell Physiol 289: C1408-C1416.
17. Chaitanya GV, Franks SE, Cromer W, Wells SR, Bienkowska M, Jennings MH, et al. (2010). Differential cytokine responses in human and mouse lymphatic endothelial cells to cytokines in vitro. Lymphat Res Biol 8 (3): 155-164.
18. Chakraborty S, Nepiyushchikh Z, Davis MJ, Zawieja DC, Muthuchamy M, (2011). Substance P activates both contractile and inflammatory pathways in lymphatics through the neurokinin receptors NK1R and NK3R. Microcirculation 18: 24-35.
19. Chatterjee V, Gashev AA, (2014). Mast cell-directed recruitment of MHC class II positive cells and eosinophils towards mesenteric lymphatic vessels in adulthood and elderly. Lymphat Res Biol 12: 37-47.
20. Chidlow JH Jr, Shukla D, Grisham MB, Kevil CG, (2007). Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol 293: G5-G18.
21. Cominelli F, Nast CC, Clark BD, Schindler R, Lierena R, Eysselein VE, et al. (1990). Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 86: 972-980.
22. Cromer W, Wang W, Zawieja SD, von der Weid PY, Newell-Rogers MK, Zawieja DC, (2015). Colonic insult impairs lymph flow, increases cellular content of the lymph, alters local lymphatic microenvironment, and leads to sustained inflammation in the rat ileum. Inflamm Bowel Dis 21 (7): 1553-1563.
23. Cromer WE, Zawieja SD, Tharakan B, Childs EW, Newell MK, Zawieja DC, (2014). The effects of inflammatory cytokines on lymphatic endothelial barrier function. Angiogenesis 17: 395-406.
24. Danese S, (2011). Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: 'brothers in arms'. Gut 60: 998-1008.
25. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, Buchler MW, (2000). Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 62: 240-248.
26. Feng L, Sun W, Xia Y, Tang WW, Chanmugam P, Soyoola E, et al. (1993). Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 307: 361-368.
27. Gashev AA, Davis MJ, Delp MD, Zawieja DC, (2004). Regional variations of contractile activity in isolated rat lymphatics. Microcirculation 11: 477-492.
28. Hanley CA, Elias RM, Movat HZ, Johnston MG, (1989). Suppression of fluid pumping in isolated bovine mesenteric lymphatics by interleukin-1: interaction with prostaglandin E2. Microvasc Res 37: 218-229.
29. Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, et al. (2005). Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet 37: 1072-1081.
30. Hata AN, Breyer RM, (2004). Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103: 147-166.
31. Hatoum OA, Miura H, Binion DG, (2003). The vascular contribution in the pathogenesis of inflammatory bowel disease. Am J Physiol Heart Circ Physiol 285: H1791-H1796.
32. Hu W, Mahavadi S, Li F, Murthy KS, (2007). Upregulation of RGS4 and downregulation of CPI-17 mediate inhibition of colonic muscle contraction by interleukin-1beta. Am J Physiol Cell Physiol 293: C1991-C2000.
33. Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K, Detmar M, (2010). Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med 207: 2255-2269.
34. Huggenberger R, Siddiqui SS, Brander D, Ullmann S, Zimmermann K, Antsiferova M, et al. (2011). An important role of lymphatic vessel activation in limiting acute inflammation. Blood 117: 4667-4678.
35. Johnson LA, Clasper S, Holt AP, Lalor PF, Baban D, Jackson DG, (2006). An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J Exp Med 203 (12): 2763-2777.
36. Johnston MG, Gordon JL, (1981). Regulation of lymphatic contractility by arachidonate metabolites. Nature 293: 294-297.
37. Karnezis T, Shayan R, Caesar C, Roufail S, Harris NC, Ardipradja K, et al. (2012). VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 21: 181-195.
38. Kehrer P, Turnill D, Dayer JM, Muller AF, Gaillard RC, (1988). Human recombinant interleukin-1 beta and -alpha, but not recombinant tumor necrosis factor alpha stimulate ACTH release from rat anterior pituitary cells in vitro in a prostaglandin E2 and cAMP independent manner. Neuroendocrinology 48: 160-166.
39. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
40. Kim H, Kataru RP, Koh GY, (2012a). Regulation and implications of inflammatory lymphangiogenesis. Trends Immunol 33: 350-356.
41. Kim JI, Urban M, Young GD, Eto M, (2012b). Reciprocal regulation controlling the expression of CPI-17, a specific inhibitor protein for the myosin light chain phosphatase in vascular smooth muscle cells. Am J Physiol Cell Physiol 303: C58-C68.
42. Lachance PA, Hazen A, Sevick-Muraca EM, (2013). Lymphatic vascular response to acute inflammation. PLoS ONE 8: e76078.
43. Mathias R, von der Weid PY, (2013). Involvement of the NO-cGMP-K(ATP) channel pathway in the mesenteric lymphatic pump dysfunction observed in the guinea pig model of TNBS-induced ileitis. Am J Physiol Gastrointest Liver Physiol 304: G623-G634.
44. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
45. Mislin H, (1961). Zur funktionsanalyse der Lymphgefässmotorik (Cavia porcellus L.). Rev Suisse Zool 68: 228-238, (German).
46. Mislin H, Rathenow D, (1962). Experimentelle untersuchungen über die bewegungskoordination der Lymphangione (Cavia porcellus L.). Rev Suisse Zool 69: 334-344, (German).
47. Mori D, Watanabe N, Kaminuma O, Murata T, Hiroi T, Ozaki H, et al. (2014). IL-17A induces hypo-contraction of intestinal smooth muscle via induction of iNOS in muscularis macrophages. J Pharmacol Sci 125: 394-405.
48. Muthuchamy M, Gashev A, Boswell N, Dawson N, Zawieja D, (2003). Molecular and functional analyses of the contractile apparatus in lymphatic muscle. FASEB J 17: 920-922.
49. Neurath MF, (2014). Cytokines in inflammatory bowel disease. Nat Rev Immunol 14: 329-342.
50. Ohama T, Hori M, Momotani E, Iwakura Y, Guo F, Kishi H, et al. (2007). Intestinal inflammation downregulates smooth muscle CPI-17 through induction of TNF-alpha and causes motility disorders. Am J Physiol Gastrointest Liver Physiol 292: G1429-G1438.
51. Ohta Y, Hayashi M, Kanemaru T, Abe K, Ito Y, Oike M, (2008). Dual modulation of airway smooth muscle contraction by Th2 cytokines via matrix metalloproteinase-1 production. J Immunol 180: 4191-4199.
52. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ, (2012). Ulcerative colitis. Lancet 380: 1606-1619.
53. Ostanin DV, Bao J, Koboziev I, Gray L, Robinson-Jackson SA, Kosloski-Davidson M, et al. (2009). T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol 296 (2): G135-G146.
54. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
55. Rehal S, Blanckaert P, Roizes S, von der Weid PY, (2009). Characterization of biosynthesis and modes of action of prostaglandin E2 and prostacyclin in guinea pig mesenteric lymphatic vessels. Br J Pharmacol 158: 1961-1970.
56. Ren J, Karpinski E, Benishin CG, (1995). Prostaglandin E2 contracts vascular smooth muscle and inhibits potassium currents in vascular smooth muscle cells of rat tail artery. J Pharmacol Exp Ther 275: 710-719.
57. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K, (1998). Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 273: 8413-8418.
58. Schneider CA, Rasband WS, Eliceiri KW, (2012). NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671-675.
59. Smith RO, (1949). Lymphatic contractility: a possible mechanism of lymphatic vessels for the transport of lymph. J Exp Med 90: 497-509.
60. Sprague AH, Khalil RA, (2009). Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 78: 539-552.
61. Van Kruiningen HJ, Colombel JF, (2008). The forgotten role of lymphangitis in Crohn's disease. Gut 57: 1-4.
62. Vigano T, Habib A, Hernandez A, Bonazzi A, Boraschi D, Lebret M, et al. (1997). Cyclooxygenase-2 and synthesis of PGE2 in human bronchial smooth-muscle cells. Am J Respir Crit Care Med 155: 864-868.
63. von der Weid PY, Muthuchamy M, (2010). Regulatory mechanisms in lymphatic vessel contraction under normal and inflammatory conditions. Pathophysiology 17: 263-276.
64. von der Weid PY, Rehal S, (2010). Lymphatic pump function in the inflamed gut. Ann N Y Acad Sci 1207 (Suppl. 1): E69-E74.
65. von der Weid PY, Rehal S, Ferraz JG, (2011). Role of the lymphatic system in the pathogenesis of Crohn's disease. Curr Opin Gastroenterol 27: 335-341.
66. Watari K, Nakao S, Fotovati A, Basaki Y, Hosoi F, Bereczky B, et al. (2008). Role of macrophages in inflammatory lymphangiogenesis: enhanced production of vascular endothelial growth factor C and D through NF-kappaB activation. Biochem Biophys Res Commun 377: 826-831.
67. Wilson RJ, Giblin GM, Roomans S, Rhodes SA, Cartwright KA, Shield VJ, et al. (2006). GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol 148: 326-339.
68. Wu TF, Carati CJ, Macnaughton WK, von der Weid PY, (2006). Contractile activity of lymphatic vessels is altered in the TNBS model of guinea pig ileitis. Am J Physiol Gastrointest Liver Physiol 291: G566-G574.
69. Zawieja DC, Davis KL, Schuster R, Hinds WM, Granger HJ, (1993). Distribution, propagation, and coordination of contractile activity in lymphatics. Am J Physiol Heart Circ 264 (4 Pt 2): H1283-H1291.